Fluicell presents T1D implant technology research at Breakthrough T1D Clinical & Research Congress

Fluicell highlighted progress in its type 1 diabetes cell-therapy implant program during the Breakthrough T1D Clinical & Research Congress in Philadelphia on Oct. 9-11. Early-stage work was presented as a scientific poster, not as clinical trial results. Management described the meeting as productive for discussions with Breakthrough T1D and Mayo Clinic on the active project. The update framed cell therapies as gaining momentum in diabetes, positioning Fluicell’s approach as differentiated within the field. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fluicell AB published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein. (C)